NCT01769703View on ClinicalTrials.gov

Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Transient Ischemic AttackMinor Ischemic Stroke
Interventions
DRUG

Dabigatran 110/150 mg BID

Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.

Trial Locations (1)

T6G2B7

University of Alberta, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT01769703 - Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke | Biotech Hunter | Biotech Hunter